Table 2 of Padma, Mol Vis 2011; 17:127-133.
Patients | Controls | |||||
---|---|---|---|---|---|---|
Genotype | n | % | n | % | O.R (95%CI) | p value |
XPD | ||||||
Asp/Asp | 84 | 40.4 | 62 | 41.1 | 1.66(0.90–3.07) | 0.11 |
Asp/Asn | 79 | 38.0 | 69 | 45.7 | 1.97(1.06–3.63) | 0.03* |
Asn/Asn | 45 | 21.6 | 20 | 13.2 | reference | |
G (Asp) | 0.59 | 0.64 | ||||
A (Asn) | 0.41 | 0.36 | 0.82 (0.60–1.12) | 0.21 | ||
Recessive model | ||||||
Asp/Asp + Asp/Asn | 163 | 78.4 | 131 | 86.8 | ||
Asn/Asn | 45 | 21.6 | 20 | 13.2 | 1.81(1.02–3.20) | 0.04* |
XRCC1 | ||||||
Arg/Arg | 90 | 43.3 | 75 | 49.7 | 1.50(0.81–2.79) | 0.20 |
Arg/Gln | 82 | 39.4 | 56 | 37.1 | 1.23(0.65–2.33) | 0.53 |
Gln/Gln | 36 | 17.3 | 20 | 13.2 | reference | |
G (Arg) | 0.63 | 0.68 | ||||
A (Gln) | 0.37 | 0.32 | 0.80(0.59–1.10) | 0.17 | ||
Recessive model | ||||||
Arg/Arg +Arg/Gln | 172 | 82.7 | 131 | 86.8 | ||
Gln/Gln | 36 | 17.3 | 20 | 13.2 | 1.37(0.76–2.46) | 0.30 |